In patients with ACS with pathogenic FH, more intensive lipid-lowering therapy (PCSK9 inhibitors, higher-intensity statins) may be necessary to further reduce LDL-C levels. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.